MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-mediated MDR. In the present study, we reported for...

Full description

Bibliographic Details
Main Authors:	Zhuo-Xun Wu, Qiu-Xu Teng, Yuqi Yang, Nikita Acharekar, Jing-Quan Wang, Min He, Sabesan Yoganathan, Jun Lin, Jian Wang, Zhe-Sheng Chen
Format:	Article
Language:	English
Published:	Elsevier 2022-05-01
Series:	Acta Pharmaceutica Sinica B
Subjects:	MET inhibitor Tepotinib Multidrug resistance ABCG2 transporter Reversal agent Combination treatment
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383521004901

Similar Items

Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test
by: Yoshihiro Miyashita, MD, et al.
Published: (2024-06-01)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
by: Shinkichi Takamori, et al.
Published: (2021-03-01)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
by: Go Makimoto, et al.
Published: (2022-05-01)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
by: Kei Kunimasa, et al.
Published: (2021-12-01)

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
by: Yukihiro Umeda, et al.
Published: (2025-01-01)

Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report
by: Rongzhen Li, et al.
Published: (2024-11-01)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
by: Brazel D, et al.
Published: (2022-05-01)

Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features
by: Yan Meng, et al.
Published: (2024-07-01)

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
by: Alessandro Inno, et al.
Published: (2023-10-01)

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report
by: Taira Ninomaru, MD, et al.
Published: (2021-03-01)

Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport
by: Chung-Pu Wu, et al.
Published: (2023-11-01)

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
by: Tomoki Tamura, et al.
Published: (2023-01-01)

Design, Synthesis, and Evaluation of New Mesenchymal–Epithelial Transition Factor (c-Met) Kinase Inhibitors with Dual Chiral Centers
by: Han Yao, et al.
Published: (2022-08-01)

Dorsomorphin attenuates ABCG2-mediated multidrug resistance in colorectal cancer
by: Xiao-Peng Li, et al.
Published: (2024-05-01)

AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer
by: Kun Liu, et al.
Published: (2021-05-01)

Measurement of tepotinib by UPLC‒MS/MS and its interaction with naringenin in rats
by: Zhe Chen, et al.
Published: (2024-11-01)

The interaction mechanism of tepotinib and α-glucosidase: A prelude to control type 2 diabetes mellitus
by: Ying Wang, et al.
Published: (2024-07-01)

Effect of physical activity on prevention and treatment of atherosclerosis: focus on activity of ABCG5 and ABCG8 genes
by: Mohsen Jafari
Published: (2019-10-01)

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
by: Zhuo-Xun Wu, et al.
Published: (2020-05-01)

Tepotinib‐induced hand‐foot skin reaction
by: Takafumi Yamano, et al.
Published: (2024-05-01)

GSK2606414 Sensitizes ABCG2-Overexpressing Multidrug-Resistant Colorectal Cancer Cells to Chemotherapeutic Drugs
by: Ze-Zhong Yu, et al.
Published: (2023-11-01)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
by: Shinkichi Takamori, et al.
Published: (2022-10-01)

Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape
by: Manon A Simard, et al.
Published: (2024-11-01)

Expression, Function and Trafficking of the Human ABCG2 Multidrug Transporter Containing Mutations in an Unstructured Cytoplasmic Loop
by: Orsolya Mózner, et al.
Published: (2023-10-01)

Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor
by: Zhuo-Xun Wu, et al.
Published: (2021-07-01)

Cellular Processing of the ABCG2 Transporter—Potential Effects on Gout and Drug Metabolism
by: Orsolya Mózner, et al.
Published: (2019-10-01)

Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells
by: Pranav Gupta, et al.
Published: (2018-02-01)

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
by: Ning Ji, et al.
Published: (2018-10-01)

Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non‐small cell lung cancer: A case report
by: Satoshi Ikeo, et al.
Published: (2023-04-01)

Ellagic Acid and Schisandrins: Natural Biaryl Polyphenols with Therapeutic Potential to Overcome Multidrug Resistance in Cancer
by: Sabesan Yoganathan, et al.
Published: (2021-02-01)

Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene
by: Hayato Tada, et al.
Published: (2020-01-01)

ABCG5 and ABCG8 gene variations associated with sitosterolemia and platelet dysfunction
by: Jose María Bastida, et al.
Published: (2021-05-01)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
by: Weiguo Feng, et al.
Published: (2020-06-01)

Cooperative transcriptional activation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 genes by nuclear receptors including Liver-X-Receptor
by: Su Sun Back, et al.
Published: (2013-06-01)

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
by: Jingqiu Wang, et al.
Published: (2020-02-01)

Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo
by: Fanpu Zeng, et al.
Published: (2020-05-01)

ABCG11 modulates cytokinin responses in Arabidopsis thaliana
by: Qianying Yang, et al.
Published: (2022-07-01)

Carborane-Based ABCG2-Inhibitors Sensitize ABC-(Over)Expressing Cancer Cell Lines for Doxorubicin and Cisplatin
by: Svetlana Paskas, et al.
Published: (2023-11-01)

An LC–MS/MS Analytical Method for Quantifying Tepotinib in Human Liver Microsomes: Application to In Vitro and In Silico Metabolic Stability Estimation
by: Mohamed W. Attwa, et al.
Published: (2023-05-01)

OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
by: Yuqi Yang, et al.
Published: (2021-02-01)